Quintiles today announced that its flagship central laboratory in Mumbai, India, has received an accreditation from the College of American Pathologists 15189SM Accreditation Program, becoming the first laboratory in Asia to receive this accreditation and meet the program's rigorous requirements for medical laboratory quality and competence established by the International Organization for Standardization (ISO).

Mr Thomas Wollman, senior vice president, Quintiles Global Laboratories said that the accreditation is further evidence of Quintiles' commitment to deliver high quality, harmonized test results to their biopharma customers globally. He added, "Quintiles has the world's largest CAP-accredited central laboratory network. We also believe we are the world's best."

CAP 15189SM   is a voluntary, non-regulatory accreditation to the ISO 15189:2007 Standard and complements CAP accreditation and other quality systems. The program optimizes processes to improve patient care, strengthens quality standards while reducing institutional errors and risks and controls costs.

Mr Anil Raghavan, managing director, Quintiles India, said, "The accreditation focuses on the continuum of care directly connected with improved patient safety and risk reduction. We are proud to be the first Asia Pacific lab to receive this accreditation, which reflects our commitment to establishing best-in-class practices in the industry."

Quintiles supports global and regional trials in almost every country in the world, with wholly owned facilities in the US, Europe, South Africa, India, China, Singapore and Japan, and a tightly coordinated network of affiliate laboratories in Argentina and Brazil. All of Quintiles laboratories operate with uniform instrumentation and standard operating procedures, delivering high quality and harmonized data.